Interpace Diagnostics (NASDAQ:IDXG) has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ:POAI).
As part of this agreement, the Companies expect to develop a pipeline of products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations.
Under the plan, Helomics will build a model using Interpace’s existing clinical data to identify druggable targets for treatment of indolent and aggressive thyroid cancers.
IDXG shares are up 11% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.